Stockscreener 앱 받기
100.28
4.19%
-4.39
시간 외 거래:
100.28
전일 마감가:
$104.67
열려 있는:
$103.93
하루 거래량:
328.48K
Relative Volume:
1.36
시가총액:
$1.19B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.99%
1개월 성능:
+9.49%
6개월 성능:
+320.90%
1년 성능:
+735.67%
1일 변동 폭
$97.19
$105.54
1주일 범위
$97.19
$105.54
52주 변동 폭
$11.89
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
100.28 | 1.24B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9%Here's What Happened - MarketBeat
Published on: 2025-12-23 22:49:55 - bollywoodhelpline.com
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path - MyChesCo
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results - MyChesCo
Palvella Therapeutics stock hits 52-week high at 112.4 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighStill a Buy? - MarketBeat
Palvella Therapeutics stock hits 52-week high at 112.4 USD - Investing.com
Palvella Therapeutics, Inc.(NasdaqCM:PVLA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Palvella Therapeutics (PVLA) Price Target Increased by 33.50% to 178.50 - Nasdaq
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Finviz
Will Palvella Therapeutics Inc. stock gain from lower inflation2025 Earnings Impact & Fast Gain Stock Tips - Улправда
Assessing Palvella Therapeutics’ Valuation After Its Rare Disease Momentum-Driven Surge in 2024 - Yahoo Finance
Buy Signal: Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownQuarterly Profit Report & AI Enhanced Execution Alerts - Улправда
Will Palvella Therapeutics Inc. stock attract ESG investorsTrade Signal Summary & Real-Time Market Sentiment Reports - Улправда
How Palvella Therapeutics Inc. stock trades before earningsJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - Улправда
Will Palvella Therapeutics Inc. stock continue upward momentumGlobal Markets & Weekly High Momentum Picks - Улправда
Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells Shares - TradingView — Track All Markets
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
What is the fair value of Palvella Therapeutics Inc. stock nowJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - DonanımHaber
Buy Signal: Is Palvella Therapeutics Inc. stock a buy for dividend growth2025 Price Momentum & AI Powered Trade Plan Recommendations - DonanımHaber
Can Palvella Therapeutics Inc. stock deliver surprise earnings beatMarket Activity Summary & Weekly High Potential Stock Alerts - ulpravda.ru
What is HC Wainwright's Forecast for PVLA FY2027 Earnings? - MarketBeat
FY2026 EPS Estimates for PVLA Decreased by Lifesci Capital - MarketBeat
Palvella Therapeutics announces topline results from Phase 2 TOIVA trial - MSN
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% Following Analyst Upgrade - Defense World
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 6.6% on Analyst Upgrade - MarketBeat
Palvella Therapeutics stock price target raised by Chardan to $174 on cVM trial - Investing.com Canada
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer - Yahoo Finance
Analyst Raises Price Target for PVLA with Maintained Buy Rating - GuruFocus
TD Cowen Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00 - MarketBeat
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Palvella Therapeutics stock price target raised to $193 at Raymond James - Investing.com Canada
Palvella Therapeutics Says US FDA Grants Potential Lesion Therapy Fast-Track Designation - marketscreener.com
Chardan Boosts Price Target on Palvella Therapeutics to $174 From $110, Keeps Buy Rating - marketscreener.com
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
FDA grants fast track designation for Palvella’s skin disease therapy By Investing.com - Investing.com Canada
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas - The Manila Times
Palvella Therapeutics Granted FDA Fast Track Designation - GlobeNewswire
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):